Histology, Department of Morphofunctional Sciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, Victor Babeș, No 8, 400012 Cluj-Napoca, Romania.
Pharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, Victor Babeș, No 8, 400012 Cluj-Napoca, Romania.
Molecules. 2024 Feb 8;29(4):778. doi: 10.3390/molecules29040778.
Endometriosis is a common gynecological condition with a complex physio-pathological background. This study aimed to assess the role of leaf extract (RiDE) as a potential therapeutic agent in reducing the size of the endometriotic lesions and modulate the plasma expression of MMP-2, MMP-9, and TGF-β1. The endometriotic lesions were induced in a rat model by the autologous transplant of endometrium. Thirty-six female rats, Wistar breed, with induced endometriosis, were divided into four groups and underwent treatment for 28 days. The CTRL group received 0.5 mL/day of the vehicle; the DG group received 1 mg/kg b.w./day dienogest; the RiDG group received 0.25 mL/kg b.w./day RiDE and the D+RiDG group received 1 mg/kg b.w./day dienogest and 0.25 mL/kg b.w./day RiDE, respectively. Rats' weight, endometriotic lesion diameter and grade, and plasma levels of MMP-2, MMP-9, and TGF-β1 were assessed before and after treatment. The administration of RiDE in association with dienogest vs. dienogest determined a lower weight gain and a reduction in diameter of the endometriotic lesions. RiDE administration restored MMP2 and MMP9 plasma levels to initial conditions. extract may help in reducing dienogest-associated weight gain, lower the size of endometriotic lesions, and have anti-inflammatory effects through MMP2 and MMP9 reduction.
子宫内膜异位症是一种常见的妇科疾病，具有复杂的生理病理背景。本研究旨在评估叶提取物（RiDE）作为一种潜在治疗剂在减少子宫内膜异位症病变大小和调节基质金属蛋白酶-2（MMP-2）、基质金属蛋白酶-9（MMP-9）和转化生长因子-β1（TGF-β1）血浆表达中的作用。通过子宫内膜自体移植在大鼠模型中诱导子宫内膜异位症。将 36 只诱导子宫内膜异位症的 Wistar 品系雌性大鼠分为四组，并进行 28 天的治疗。CTRL 组每天接受 0.5 mL 载体；DG 组每天接受 1mg/kg bw/天地诺孕素；RiDG 组每天接受 0.25 mL/kg bw/天 RiDE；D+RiDG 组分别接受 1mg/kg bw/天地诺孕素和 0.25 mL/kg bw/天 RiDE。治疗前后评估大鼠体重、子宫内膜异位症病变直径和分级以及 MMP-2、MMP-9 和 TGF-β1 的血浆水平。与地诺孕素相比，RiDE 联合地诺孕素的给药导致体重增加减少和子宫内膜异位症病变直径减小。RiDE 给药将 MMP2 和 MMP9 的血浆水平恢复到初始状态。RiDE 提取物可能有助于减少地诺孕素相关的体重增加，降低子宫内膜异位症病变的大小，并通过降低 MMP2 和 MMP9 发挥抗炎作用。
